Sai Parenterals
Sai Parenterals Share Price Chart
Sai Parenterals last traded at ₹504.55 (2026-10-13). Over the past month the stock moved -3.9%, three months the stock moved +4.3%. Its closing range over 52 weeks is ₹405.70 – ₹551.90, with the latest close 8.6% below the high.
Closing prices up to 2026-10-13.
About Sai Parenterals
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
Business Profile[1][2] Sai Parenteral is a diversified pharmaceutical formulations company engaged in R&D, manufacturing, and commercialization of products across both domestic and international markets. Over time, the company has evolved from being a parenteral-focused player into a full-fledged diversified formulations platform, significantly reducing its dependency on injectables in the process.
Fundamentals
Quarterly Results
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 178.67 | 23.52 | 13.16 | 7.92 | 1.79 |
| Mar 2026 | 197.93 | 26.10 | 13.19 | 13.16 | 2.98 |
| Dec 2025 | 96.15 | -3.56 | -3.70 | -6.66 | -1.80 |
| Jun 2025 | 33.39 | 4.74 | 14.20 | 1.42 | 0.52 |
Annual Financials
In the latest year (Mar 2026), Sai Parenterals reported sales of ₹381.00 crore (+133.7%) and net profit of ₹14.00 crore (+0.0%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 381.00 | 39.00 | 10.00 | 14.00 | 3.23 |
| Mar 2025 | 163.00 | 39.00 | 24.00 | 14.00 | 5.43 |
| Mar 2024 | 154.00 | 32.00 | 21.00 | 8.00 | 6.36 |
| Mar 2023 | 97.00 | 19.00 | 19.00 | 4.00 | 6.13 |
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Sales growth | +58.8% | +5.8% | +133.7% |
| Operating profit growth | +68.4% | +21.9% | +0.0% |
| Net profit growth | +100.0% | +75.0% | +0.0% |
| EPS growth | +3.8% | -14.6% | -40.5% |
| OPM % | 21.0% | 24.0% | 10.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
Sai Parenterals is trading at ₹509, just 3.3% below its 52W high of ₹523.4, with strong 1-year returns of 27.25% post-IPO listing. However, the stock faces fundamental headwinds: P/B of 10.35x is expensive relative to a modest ROE of 6.8% (Mar 2025), and the latest quarterly EPS of ₹2.11 (Sep 2025) is sharply lower than the annualized Mar 2025 EPS of ₹5.43, signaling earnings deterioration. While balance sheet leverage has improved significantly (D/E from 1.61 to 0.38), the core concern is weak and declining profitability combined with elevated valuation.
- Strong balance sheet deleveraging: D/E improved from 1.61 (Mar 2024) to 0.38 (Sep 2025), with borrowings halved to ₹78 Cr, reducing refinancing and solvency risk.
- Solid ROCE of 17.0% (Mar 2025) with upward trajectory from 16.0% (Mar 2024), indicating capital-efficient operations despite modest ROE, typical of growing pharma firms.
- Robust cash flow generation: OCF of ₹33 Cr (Mar 2025) vs net profit of ₹14 Cr signals high-quality earnings backed by real cash conversion; prior year OCF was negative at ₹-30 Cr, showing operational turnaround.
- Sharp earnings deterioration in latest quarter: EPS Sep 2025 (₹2.11) is 61% below Mar 2025 annualized EPS (₹5.43), indicating significant profitability contraction or one-time charges—requires clarification on structural vs. cyclical nature of decline.
- Expensive valuation with weak ROE: P/B of 10.35x is difficult to justify given ROE of only 6.8%, implying the stock is pricing in substantial future earnings growth that is not yet evident; any earnings miss could trigger significant multiple compression.
AI-generated analysis for informational purposes only — not SEBI-registered investment advice.
See Full AI Analysis — Free FREE →Latest News
-
Sai Parenterals acquires 60% stake in Prathyak Laboratories for Rs 15 crore
-
Sai Parenterals gains after arm renews 204 cr OTC supply agreement - Business Standard
-
Sai Parenterals gains after arm renews 204 cr OTC supply agreement - Business Standard
-
Sai Parenterals gains after arm renews 204 cr OTC supply agreement - Business Standard
-
Sai Parenterals gains after arm renews 204 cr OTC supply agreement - Business Standard
-
Sai Parenterals gains after arm renews 204 cr OTC supply agreement - Business Standard
-
Sai Parenterals' arm renews OTC medicines supply agreement with Australian pharmacy network
-
Sai Parenterals Subsidiary Signs ₹1,300 Crore Australia Supply Deal; Shares Surge
-
Sai Parenterals arm signs OTC medicines supply agreement with Australian pharmacy network - Business Standard
-
Sai Parenterals Ltd Share/Stock Price Live Today | The HinduBusinessLine - BusinessLine
Frequently Asked Questions
What is Sai Parenterals's current stock price?
Sai Parenterals shares were last quoted at ₹504.55 (+2.2% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Sai Parenterals?
Sai Parenterals has a price-to-earnings (P/E) ratio of 106.81 and a price-to-book (P/B) ratio of 4.45. The industry P/E is 53.33.
What is the 52-week high and low of Sai Parenterals?
The 52-week high of Sai Parenterals is ₹705.00 and the 52-week low is ₹400.00.
What is the market cap of Sai Parenterals?
The market capitalisation of Sai Parenterals is about ₹2,217.80 crore.
Is Sai Parenterals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Sai Parenterals has a 3-year ROE of 9.00%, 3-year profit growth of 48.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Sai Parenterals?
Promoters hold about 51.16% of Sai Parenterals.
Which sector does Sai Parenterals belong to?
Sai Parenterals belongs to the Pharmaceuticals & Drugs sector.